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Abstract
Objectives: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease associated with neuro-psychiatric
(NP) manifestations. Frequency and patterns of neuro-psychiatric systemic lupus erythematosus (NPSLE) vary substan-
tially between patients. We conducted a systematic review (SR) of the literature and examined prevalence and character-
istics of NPSLE in the Swiss SLE cohort study (SSCS).
Methods: The SR search was performed between January 1999 and January 2020. We included prospective/cross-
sectional studies focusing on NPSLE. We secured study characteristics, cohort compositions and frequencies of NP
manifestations, assessed heterogeneity across reports and investigated sources of variation using meta-regression
models. Regarding the SSCS, we reviewed all patients included and classified NP manifestations.
Results: The SR searches identified 530 studies. We included 22 studies in our meta-analysis, the mean frequency of
NPSLE ranged from 10.6% to 96.4%. The frequency of NPSLE in the SSCS was 28.1%. Severe events including cere-
brovascular insults, seizures and psychosis appeared in 7.1%, 5.3% and 6.5% respectively. There was a linear relationship
between duration of SLE and cumulative incidence of NPSLE.
Conclusions: The spectrum of NPSLE is very broad. The diagnostic work-up and rates of reported manifestations
varied substantially across studies. We call for concerted efforts and consensus regarding definitions of NPSLE that will
facilitate accurate diagnosis and attribution to SLE, particularly with a view to timely intervention and patient outcomes.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic, sys-
temic autoimmune disease, often presenting with
neuro-psychiatric manifestations. The frequency and
patterns of severe neurologic and psychiatric events in
SLE are extremely heterogeneous and remain incom-
pletely understood. In the literature, the occurrence of
neuro-psychiatric systemic lupus erythematosus
(NPSLE) varies from 21-95%.1–4 The wide range of
NPSLE prevalence is mainly due to the difficulty
of attributing NP events to SLE and classification of
1Department of Immunology, University Hospital of Zurich, Zurich,
Switzerland
2Medignition Healthcare Innovations, Zurich, Switzerland
3Division of Immunology and Allergy, Lausanne University Hospital,
Lausanne, Switzerland
4Neurologic Clinic and Policlinic, Departments of Medicine and
Biomedicine, University Hospital Basel and University of Basel, Basel,
Switzerland
5Departement of Psychiatry, University Hospital of Zurich, Zurich,
Switzerland
6Departement of Neurology, University Hospital of Zurich, Zurich,
Switzerland
Corresponding author:










events, which leads to inconsistent reporting of its inci-
dence.5–8 With regard to the course of NPSLE, as per
current knowledge, at least half of NP events occur
within the first 1-2 years after SLE diagnosis.2,5,9–11
According the American College of Rheumatology
(ACR) nomenclature and case definitions from 1999, in
SLE 19 neuro-psychiatric syndromes are described.12
These syndromes are differentiated in 12 central and
seven peripheral, diffuse or focal manifestations.1,12
Syndromes range from subtle abnormalities like head-
ache, cognitive dysfunction or mood disorder to severe
presentations such as seizures, psychosis or strokes. In
clinical practice, expert physician judgement based on
clinical tests remains the most appropriate reference
standard for NPSLE diagnosis.5,11 Uncertainty regard-
ing atypical presentations may delay targeted and
timely interventions. In this study, we evaluated the
occurrence and distribution of neuro-psychiatric man-
ifestations in a large prospective nationwide cohort of
Swiss SLE patients13 and performed a systematic liter-
ature review to contextualize our findings.
Methods
Systematic review/meta-analysis
Our review of studies regarding NPSLE has been reg-
istered on Prospero. Included were studies published
between January 1999 and January 2020 investigating
the occurrence of NP events in SLE patients, provided
they met the following criteria: 1) prospective or cross-
sectional study design; 2) the use of the ACR criteria to
establish a diagnosis for SLE; 3) definition of NP
events by applying the ACR classification from 1999.
Excluded were retrospective cohort studies or case
reports and studies that presented duplicate data of
the same cohort in a similar time period as another
included study.
Searches were conducted in electronic databases, i.e.
Pre-(Medline), PubMed, interface and the Science
Citation Index database for papers citing relevant stud-
ies. We also checked the reference lists of all papers and
reviews. Finally, we contacted authors of pertinent
papers to clarify ambiguities and request the availabil-
ity of additional data. Abstracts published in all lan-
guages of the identified articles were reviewed (A.M.).
Retrospective studies, case reports and reviews were
excluded, as well as papers not investigating the topic
of NPSLE. The remaining studies were read in full text
and checked for inclusion and exclusion criteria (A.
M.). The process of data extraction was performed by
two independently working investigators to assure uni-
formity of the data (A.M. and C.W.). The extraction
files were subsequently compared, and discrepancies
corrected. For each study included, we recorded the
following data: study design, total number of SLE
patients, number of NPSLE patients, number of NP
events and patient characteristics including gender, eth-
nicity, mean age at SLE diagnosis, mean age at study
assessment, duration from SLE diagnosis to NP event,
cardiovascular risk factors, autoantibodies if available,
as well as medication received. Furthermore, we con-
ducted data on the mean ACR criteria for SLE, the
mean SELENA-SLEDAI and the mean SDI score.
Prevalence estimates for NPSLE in each study and
for each of the 19 NP manifestations individually were
calculated with their 95% confidence intervals.
Prevalence is shown as percentage of the entire study
population (SLE patients). In order to minimize the
risk of bias, a quality assessment was carried out for
each study. We assessed how representative the study
cohorts were, the accuracy of the outcome measure-
ments, the identification of confounders and the meas-
ures taken to minimize their influence. We also
examined the presentation of outcomes, whether
patient enrolment was consecutive, the number and
handling of dropouts, the duration of follow-up and
finally, the generalizability of study results to patients
seen in everyday clinical practice. Despite substantial
unexplained heterogeneity of 22 high quality studies,
we performed a random effects meta-analysis, calculat-
ing exact 95% confidence intervals using the Stata 16.1
routine “metaprop”. All statistical analyses were per-
formed using the Stata 16.1 statistics software package
(StataCorp. 2019. Stata Statistical Software: Release
16. College Station, TX: StataCorp LLC.)
Swiss SLE cohort study
Study design. This cross-sectional and retrospective
study encompasses data collected between April 2007
and August 2019 from 688 patients sequentially includ-
ed in the Swiss SLE Cohort Study (SSCS) form eight
tertiary centers located in Switzerland. Patient recruit-
ment included both incident and prevalent cases of
SLE. Patients were seen at inclusion and then annually
by specialists from Clinical Immunology, Internal
Medicine, Nephrology and Rheumatology. Clinical
data as well as biological characteristics were collected
as previously published.13 This study complies with the
Declaration of Helsinki and was approved by the local
ethics board (BASEC-Nr. 2019-01807). Patients gave
their written consent for inclusion in the SSCS
database.
Patients. Chart reviews of all SSCS cohort patients were
performed to obtain a complete reporting of NP man-
ifestations. Patients without NP events served as a con-
trol group. All patients fulfilled at least 4 of the 11
revised ACR criteria.14,15 At time of database
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inclusion, ACR criteria were documented. The addi-
tionally assessed parameters included age, gender,
ancestry, cardiovascular risk factors, smoking status,
date of first SLE manifestation and time of SLE diag-
nosis. Preceding as well as newly occurring NP events
and the time lag between NP event and SLE diagnosis
were recorded. At the time of the patients’ visits a panel
of autoantibodies (ANA and its specificities anti-
dsDNA, anti-Sm, antiphospholipid (aPL) including
lupus anticoagulant (LA), anticardiolipin (aCL), and
beta 2 glycoprotein I (IgG and IgM), anti-SSA and
anti-U1-RNP) were collected. Disease activity was
assessed using the SELENA-SLEDAI score,16 while
cumulative organ damage was assessed using the
ACR/SLICC damage index (SDI).17
Cardiovascular risk factors. Cardiovascular risk factors
included hyperlipidaemia, diabetes mellitus, arterial
hypertension, and cigarette smoking and were defined
by a clearly documented history.
NP events. NP events were defined according to the 19
ACR nomenclature and case definitions for NPSLE.12
For patients suffering from more than one NP event,
each event was documented separately. Screening for
NP events was performed primarily by clinical evalua-
tion by the local interdisciplinary attending team.
Diagnosis was supported with appropriate additional
investigations if indicated, as per the ACR nomencla-
ture of 1999. Specific investigations for NP disease such
as brain imaging and cognitive testing were not per-
formed routinely on all patients but only if indicated
following clinical assessment. Patients were followed
up annually, or at shorter intervals when an event
occurred.
Statistical analyses. Values are documented as the
mean standard deviation, unless otherwise indicated.
The relationship between occurrence of a NP event and
sex, ethnicity, cardiovascular risk factors, ACR crite-
ria, SELENA-SLEDAI severity score SDI as well as
autoantibodies was assessed using multivariate logistic
regression analysis. Within the subset of the register,
where the onset date of SLE (prior to register entry)
and time point of first NPSLE was available (548/688;
79.7%) we performed a time-to-event analysis using a
Cox regression model to assess the relationship
between time point of the occurrence of different
NPSLE manifestations in the disease course.
Results
Systematic review/meta-analysis
We identified 530 records through searching databases,
of which 25 met the inclusion criteria. Twenty-two
studies qualified for quantitative analysis
(Figure 1).4,10,11,18–35 Nineteen of 25 studies were
single-centered. The mean number of patients per
study was 275.2 (SD 328.6). The total number of
patients in all studies was 6’055, of which 2’569
(weighted mean, random effects model: 0.53 (95% CI:
0.39 to 0.67)), experienced at least one NP event with a
mean of 1.9 events per NPSLE-patient (SD 0.6). The
majority of patients were female (89.6%) with an aver-
age age at study inclusion of 36.5 years (SD 7.1) and an
average disease duration of 7.3 years (SD 3.6). Data
regarding ethnicity was available in 70% of the studies,
with predominantly Caucasians observed. The mean
value of SELENA-SLEDAI score was 10.6 (SD 7.4)
and the mean SDI was 1.6 (SD 1.2). Study character-
istics of the reviewed literature and flow chart of the
inclusion process are shown in Table 1 and Figure 1.
The overall NPSLE prevalence when all studies were
pooled together was 52.2% (Figure 2). A large propor-
tion of events (4407, 93.7%) was related to the CNS.
The most common NP syndromes were headache
(1394/4702), mood disorder (770/4702) and cognitive
dysfunction (554/4702). Demyelinating syndrome,
Guillain-Barre syndrome, autonomic disorder, myas-
thenia gravis and plexopathy each showed a prevalence
rate of less than 0.5%. The cumulative prevalence of
each NP syndrome of the different studies is shown in
Table 2.
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SSCS
Patient characteristics. A total of 688 patients were regis-
tered prospectively in the SSCS database of which 583
(84.7%) were female. Patients were predominantly
Caucasian (556; 80.8%), which reflects the ethnic dis-
tribution in Switzerland.36 Mean age at SLE diagnosis
was 37.1 years (SD 15.9), mean age at SSCS inclusion
was 44.3 years (SD 15.6) with a mean SLE disease
duration of 9.3 years (SD 10.1) (Table 3).
Cardiovascular risk factors. The prevalence of smoking
was 36.5% (251/688), of arterial hypertension 22.9%
(158/688), diabetes mellitus 4.5% (31/688) and hyper-
lipidemia 9.4% (66/688).
SLE specific parameters. The mean number of ACR cri-
teria was 5.2 (SD 1.6). The mean SDI was 1.5 (SD 2.3).
The SLEDAI for the entire cohort was 6.7 (SD 7.7).
We observed the following frequencies of autoantibod-
ies (ab) in the SSCS cohort: ANA 97.2% (669/688),
anti-dsDNA-ab 65% (447/688), anti-Sm-ab 20.2%
(139/688), aPL-ab 41.7% (287/688), anti-SSA-
ab 44.7%) (242/688) and anti-U1-RNP-ab 29.3%
(121/688).
NPSLE. The nervous system (NS) was involved in 193 of
688 patients (28.1%). Isolated involvement of the cen-
tral nervous system (CNS) was present in 136 patients
(70.5%) and isolated involvement of the peripheral ner-
vous system (PNS) was present in 34 patients (17.6%),
in 23 patients (11.9%) both systems were involved. The
193 patients had 295 events, which results in 1.5 events
per patient suffering from NPSLE with a range from 1-
6 events, encompassing 16/19 NP manifestations. The
most common CNS manifestations were headache
(n¼ 51) followed by cerebrovascular disease (n¼ 49),
psychosis (n¼ 45) and seizures (n¼ 37). Among the
PNS manifestations, the most common was peripheral
polyneuropathy (n¼ 25). We did not observe demye-
linating syndrome, autonomic disorder and anxiety dis-
order. The prevalence of NPSLE of the SSCS
contextualized with the relevant literature is outlined
in Table 2.
Comparison of patients with and without NPSLE in
the SSCS
SLE specific parameters. The number of ACR criteria in
patients with NPSLE was higher compared to non-
NPSLE subjects (5.5; SD 1.9 vs 5.0; SD 1.4;
p< 0.001). NPSLE patients also had an increased
SDI (2.2; SD 3.0 vs. 1.1; SD 1.9; p< 0.001).
The frequency of autoantibodies did not differ sig-
























































































































































































































































































































































































































































































































































































We exclusively investigated the occurrence of aPL-
antibodies in patients with cerebrovascular disease.
They are clearly associated with the presence of cere-
brovascular disease in patients with NPSLE (33/49 vs.
254/639; p< 0.001).
Cardiovascular risk factors. Arterial hypertension (60/193
vs. 98/495; p¼ 0.002) and hyperlipidemia (28/193 vs.
39/495; p¼ 0.014) were more common among patients
with NPSLE. With regard to smoking (115/193 vs. 136/
495; p¼ 0.735) and diabetes mellitus (13/193 vs. 18/495;
p¼ 0.078) differences were not significant.
Course of NPSLE in the SSCS
In the analysis regarding the temporal occurrence of
the first NP event the mean time lag between the diag-
nosis of SLE and NP presence was 4.5 years (range 0.1
to 16.1 years). A comparison of the different NP man-
ifestations did not reveal any major differences in the
temporal course of the individual events (Figure 3).
Discussion
Our study has two findings: over two dozen studies
addressed the prevalence of neuro-psychiatric manifes-
tations in SLE and we observed a striking range and
diversity of clinical patterns in reporting NPSLE across
studies, including our analysis of the SSCS cohort that
could not be explained by divergent study
characteristics.
SSCS patients suffering from NPSLE documented
higher cumulative organ damage (SDI) and higher
than average number of fulfilled ACR criteria com-
pared to patients without NP events. The association
of NPSLE with greater morbidity and mortality
has already been described in numerous
studies.4,11,18–24,37–40 The higher scoring of cumulative
organ damage and also ACR criteria in patients with
NPSLE suggest that NP events in SLE are a marker for
a severe disease course with increased organ damage.
In the analysis of the SSCS patients, arterial hyper-
tension (31.1% vs. 19.8%) and hyperlipidemia (14.5%
vs.7.9) are positively associated with NP events.
Patients with SLE have an increased cardiovascular
risk and blood pressure and serum cholesterol levels
are positively associated with cardiovascular
events.41–45 Accelerated atherosclerosis and its long-
term sequelae are most probably also responsible for
NP events among patients with SLE. Therefore, car-
diovascular risk factors in SLE patients should be
treated aggressively to prevent the occurrence of car-
diovascular and NPSLE events. However, traditional























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































cardiovascular risk factors do not fully explain the high
incidence of vascular events.46 Additional inflammato-
ry processes involving antibodies and cytokines are
likely to contribute to further neuropsychiatric
damage. In a recent study, it was shown that anti-
nervous system (NS) antibodies, most prevalently
anti-MOG antibodies, are significantly associated
with NPSLE. Anti-neuronal antibodies have to cross
the blood-brain barrier to cause damage in the NS, it is
conceivable that a disruption of blood-brain/blood-
nerve barrier integrity may be mediated by vasculop-
athy that enables and drives autoantibody-mediated
inflammation in the NS tissue.47–49 In accordance
with the current literature we demonstrated that
elevated values for aPL-ab are associated with the pres-
ence of cerebrovascular disease (33/49 vs. 254/639;
p< 0.001).21,25–27,50 We did not find a higher preva-
lence of autoantibodies against dsDNA, Sm, SSA or
U1-RNP in patients with NPSLE in general. Although
anti-dsDNA- as well as anti-ribosomal-P-antibodies
may be related with NPSLE, there is little agreement
on positive or negative correlations.2,18,49–52
In the SSCS, NP events occurred even ten years after
SLE diagnosis. This contradicts previously published
studies in which NP events are described at disease
onset or within the first 1-2 years after SLE diagno-
sis.1,2,5,9–11,18,20 Rather, we found a linear relationship
between duration of follow-up and the probability of
Table 3. Patient characteristics of the SSCS.
Total NPSLE patients Non-NPSLE patients P value
Patients (%) 688 (100) 193 (28.1) 495 (71.9)
Gender, female (%) 583 (84.7) 159 (82.4) 424 (85.7)
Ethnicity (%)
Caucasian 556 (80.8) 156 (80.8) 400 (80.8)
African 46 (6.7) 11 (5.8) 35 (7.1)
Asian 59 (8.6) 16 (8.4) 43 (8.7)
Native American 26 (3.8) 0 (0) 26 (5.3)
Other 1 (0.1) 0 (0) 1 (0.1)
Age at first diagnosis, years (mean SD) 37.1 15.9 36.5 16.1 37.3 15.9
Age at study inclusion, years (mean SD) 44.3 15.6 46.1 15.3 43.7 15.7
Disease duration, years (mean SD) 9.3 10.1 11.7 11.6 8.3 9.3
Cardiovascular risk factors (%)
Smoking (incl. former smoking) 251 (36.5) 115 (59.6) 136 (27.5) 0.735
Arterial hypertension 158 (22.9) 60 (31.1) 98 (19.8) 0.002
Diabetes mellitus 31 (4.5) 13 (6.7) 18 (3.6) 0.078
Hyperlipidemia 66 (9.4) 28 (14.5) 39 (7.9) 0.014
SELENA-SLEDAI Score (mean SD) 6.7 7.7 10.0 10.5 5.4 5.8 <0.001
SDI Score (mean SD) 1.5 2.3 2.2 3.0 1.1 1.9 <0.001
ACR criteria (mean SD) 5.2 1.6 5.5 1.9 5.0 1.4 <0.001
Cumulative ACR manifestations (%)
Malar rash 263 (38.2) 73 (37.8) 190 (38.4)
Discoid rash 136 (19.8) 41 (21.2) 95 (19.2)
Photosensitivity 324 (47.1) 97 (50.3) 227 (45.9)
Oral ulcers 194 (28.2) 54 (28.0) 140 (28.3)
Arthritis 489 (71.1) 141 (73.1) 348 (70.3)
Pleuritis 147 (21.4) 42 (21.8) 105 (21.2)
Pericarditis 124 (18.0) 42 (21.8) 83 (16.8)
Renal disorder 261 (37.9) 91 (47.2) 170 (34.3)
Seizures 32 (4.7) 32 (16.6) 0 (0)
Psychosis 40 (5.8) 40 (20.7) 0 (0)
Haematological disorder 412 (59.9) 107 (55.4) 305 (61.6)
Auto antibodies (%)
ANA 669 (97.2) 184 (95.3) 485 (98.0)
Anti-dsDNA-Ab 447 (65.0) 133 (68.9) 314 (63.4)
Anti-Sm-Ab 139 (20.2) 41 (21.2) 98 (19.8)
Anti-phospholipid-Ab 287 (41.7) 85 (44.0) 202 (40.8)
Anti-SSA-Ab 242 (44.7) 68 (35.2) 174 (35.2)
Anti-U1-RNP-Ab 121 (29.3) 35 (18.1) 86 (17.4)
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occurrence of NP events, both overall and for specific
manifestations, such as stroke, seizures and psychosis
(Figure 3).
The prevalence of NPSLE differs largely in the vari-
ous studies and ranges from 10.6% to
96.4%.4,10,11,18,35,50 The prevalence of 28% within the
SSCS cohort seems to be underreported when compared
to the current literature (Figure 2). However minor NP
events including mild cognitive dysfunction, headache,
mild depression, anxiety and ENMG-negative polyneur-
opathy are common and nonspecific features and differ
hardly between SLE patients and the normal popula-
tion.30 These subtle NP manifestations cause the large
prevalence differences between studies about NPSLE.2
Standard clinical practice applied by physicians does not
routinely include assessments for cognitive dysfunction
and mood disorders with test batteries as proposed by
the ACR committee. Psychiatric diagnoses of mood dis-
order, anxiety and cognitive dysfunction, should be
defined according to the Diagnostic and Statistical
Manual of Mental Disorders (DSM-V) criteria usually
applied in psychiatry.53 But neuropsychological test bat-
teries to diagnose cognitive dysfunction are time con-
suming and not regularly performed during follow up
visits or within studies.10,19,22,26 Due to the lack of the
above-mentioned testing, none of the studies included in
our review distinguished between e.g. mild or severe
depression, cognitive dysfunction, and so forth.
Therefore, a prevalence analysis of NPSLE only consid-
ering major events in our meta-analysis by omitting the
five syndrome-categories, that are considered as minor
and mild forms, would not be correct.
Prevalence of major NP events with clear diagnostic
criteria including movement disorder, seizure and
stroke, did not differ much between studies (Table 2).
The most frequent major NP events in the SSCS were
cerebrovascular disease, psychosis and seizures. This is
in line with the current literature, also shown in
Table 2.4,10,11,18–35 Five of the 19 ACR case definitions
including demyelinating syndrome, Guillain-Barre syn-
drome, autonomic disorder, myasthenia gravis and
plexopathy, were underrepresented or not represented
at all in the SSCS. This is despite the fact that our
cohort is sufficiently large to be able to make general
statements. However, certain NP syndromes are also
scarcely present in other large cohorts (Table 2).
Limitations
There are a number of potential limitations to our
cohort study. As a cross-sectional study, the validity
of disease history depends on the documentation of
past disease episodes. However, since the SSCS data
were collected prospectively, a certain reliability of
the documentation can be assumed. Therefore, we
think that this is unlikely to have had a substantial
effect on the prevalence rates of the NP syndromes.
In addition, SSCS is more likely to include patients
with a more severe course of the disease since they
were recruited in tertiary centers. Another downside
of the study is the lack of use of the test batteries
defined by ACR for the diagnosis of cognitive impair-
ment and mood disorder. However, these tests have not
been used by most of the reviewed literature,10,19,22,26
since they are very time consuming for daily practice.
Furthermore, we did not differ between primary and
secondary NP events, as there is no clinically reliable
method to determine the attribution of NP events to
SLE with certainty.
Figure 3. Kaplan-Meier curve of NP occurrence over 10 years of follow-up, overall and stratified for stroke, seizures and psychosis.
1574 Lupus 30(10)
The studies included in the meta-analysis showed a
high heterogeneity in the frequency of neuro-psychiatric
syndromes. We tried to reduce this variability by includ-
ing only prospective studies from the beginning. A
potential bias is the various ethnicities represented in
different studies. Several studies examined only a
single ethnic group, while others looked at ethnically
diverse groups. We also included studies with both
adults and pediatric patients, which may have increased
the heterogeneity of the results. However, the occurrence
of a publication bias is relatively unlikely, as there is no
“wrong” or “right” in the investigation of frequencies.
Conclusion
In summary, there are large differences in the frequency
of NPSLE in comparison to individual studies. This is
mainly due to the common symptoms headache, anxi-
ety, mood disorders, depression and psychosis being
categorized under the criteria of NPSLE. It should be
discussed whether all SLE patients should receive rou-
tine neuropsychological testing and imaging at regular
intervals. On one hand, this would provide more clarity
regarding the prevalence of so-called “minor” events in
SLE patients; on the other hand, it would enable
prompt intervention in case of their occurrence.
Furthermore, the temporal occurrence of symptoms
can present at different stages of the disease and as
clinicians, it is important to be aware that neuro-
psychiatric events can often present many years after
an initial SLE diagnosis.
We call for concerted interdisciplinary teamwork
within cohort studies including the expertise of neurol-
ogists and psychiatrists to provide a better understand-
ing of NPSLE. Moreover, mechanisms of psychiatric
lupus manifestations require a better understanding in
order to establish objective biomarkers. Due to these
minor symptoms, there is the need for broad consensus
regarding stringent definitions of neuro-psychiatric
SLE manifestations that facilitate accurate diagnosis,
particularly with a view to timely intervention and
improving patient outcomes.
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